Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 10,545 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

NCT06503900
View directory record Official record
Conditions
Birth Outcomes, Safety, Adverse Event Following Immunization
Interventions
mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

NCT03525444
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-445/TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
53
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 30, 2026, 4:28 PM EDT
Not listed Phase 3 Interventional

ARISE - Aggressive Reduction of Inflammation Stops Events

NCT00066898
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease, Myocardial Infarction, Unstable Angina
Interventions
AGI-1067
Drug
Lead sponsor
AtheroGenics
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
128
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2006 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03548987
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Anniston, Alabama • Fresno, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 3 Interventional

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

NCT05439616
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Anaheim, California • Imperial, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 30, 2026, 4:28 PM EDT
Active, not recruiting No phase listed Observational

COMPASSION S3 Post-Approval Study

NCT04860765
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Pulmonary Valve; Obstruction
Interventions
SAPIEN 3 THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

NCT01055314
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions
Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 49 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
121
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia

NCT00115804
View directory record Official record
Conditions
Juvenile Primary Fibromyalgia Syndrome (JPFS), Fibromyalgia
Interventions
Fluoxetine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
13 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 30, 2026, 4:28 PM EDT
Terminated Phase 3 Interventional Results available

Study of Tecovirimat for Human Mpox Virus

NCT05534984
View directory record Official record
Conditions
MPOX
Interventions
Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

NCT05375838
View directory record Official record
Conditions
SARS-CoV-2, Influenza
Interventions
mRNA-1073, mRNA-1010, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
14
States / cities
Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 30, 2026, 4:28 PM EDT
Completed No phase listed Observational Results available

Clinical Utility of Postoperative Hemoglobin Testing

NCT04170764
View directory record Official record
Conditions
Anaemia Postoperative
Interventions
Not listed
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 30, 2026, 4:28 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

NCT03771664
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 30, 2026, 4:28 PM EDT
Recruiting Early Phase 1 Interventional

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

NCT04655404
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Larotrectinib, Larotrectinib surgical
Drug · Procedure
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

NCT04313504
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Trisha Wise-Draper
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed No phase listed Observational

Ultrasound Quantification of Liver Fat

NCT04523584
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Magnetic Resonance Imaging (MRI), Ultrasound Imaging
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
16 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 30, 2026, 4:28 PM EDT
Terminated Phase 2 Interventional

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

NCT03795428
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046) Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

NCT01080807
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Matching Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

NCT02621892
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
111
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

NCT03836209
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
44
States / cities
Scottsdale, Arizona • Clovis, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Terminated Phase 2 Interventional

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00053833
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
irinotecan
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
99
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 30, 2026, 4:28 PM EDT
Recruiting Not applicable Interventional

Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR

NCT05459233
View directory record Official record
Conditions
Aortic Valve Stenosis, Aortic Valve Regurgitation, Prosthesis Failure
Interventions
Doppler-echocardiography, Invasive hemodynamic measurements
Procedure
Lead sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
San Francisco, California • Hollywood, Florida • Royal Oak, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Not applicable Interventional Results available

Supplement to Hospital to Home Outcomes

NCT03224130
View directory record Official record
Conditions
Hospitalized Patients
Interventions
Nurse Phone Call, Standard of Care
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
966 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

NCT00762034
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pemetrexed, Paclitaxel, Carboplatin, Bevacizumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
67
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Alhambra, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 2 Interventional

ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects

NCT03687632
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Indianapolis, Indiana • Edgewood, Kentucky • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 30, 2026, 4:28 PM EDT